HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 11-26-2013, 01:31 PM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Australia study: Denosumab in Young Patients With Primary Breast Cancer

A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer


Trial Summary: This is a prospective, single arm phase IIa trial in which patients with early breast cancer
will receive pre-operatively two doses of denosumab 120mg subcutaneously one week apart
(maximum 12 days) followed by surgery. Tumor, normal breast tissue and blood samples will be
collected at baseline and at surgery. Post-operative treatment will be at the discretion of
the investigator.

Primary objective: to determine if a short course of RANKL inhibition with denosumab can
induce a decrease in tumor proliferation rates as determined by Ki67 immunohistochemistry
(IHC) in newly diagnosed, early stage breast cancer in pre-menopausal women.

Secondary objectives:

- To determine the number of absolute Ki67 responders after a short course of denosumab
(defined as <2.7% IHC staining in the post treatment tumor biopsy).

- To determine the effects of a short course of denosumab on serum C-terminal telopeptide
levels (CTX).

- To determine the effects of a short course of denosumab on RANK/RANKL gene expression
and signaling as assessed by immunohistochemistry (IHC) and gene expression profile in
the tumor.

- To determine the effect of a short course of denosumab on tumor apoptosis rates using
IHC

- To determine the effect of a short course of denosumab on modulating the immature
mammary epithelial cell populations in the tumor.

- To determine the effect of a short course of denosumab on estrogen signaling pathways
in the tumor.

- To determine the effect of a short course of denosumab on various immune - To determine
effect of safety profile of denosumab
Recruitment Status: Recruiting
Focus of the trial: Primary Purpose: Treatment
Phase of the trial: Phase 2
Ethics Approval: N/A
Location of trial: Royal Melbourne Hospital - Victoria,
-- Contact --
Please contact the recruitment facility


http://www.australianclinicaltrials....-breast-cancer
'lizbeth is offline   Reply With Quote
Old 11-29-2013, 03:55 PM   #2
donocco
Senior Member
 
Join Date: Oct 2013
Posts: 256
Re: Australia study: Denosumab in Young Patients With Primary Breast Cancer

Interesting. Denosumab inhibits the Receptor Activator of Nuclear Factor Kappa Beta or that Rankl abbreviation. Nuclear Factor Kappa Beta or NFK-B is very active in the growth, motility and metastasis of cancer cells.

NSAIDS like Aspirin and Motrin also inhibit NFK-B. New information states they actually stimulate it but it becomes inactive. It gets confusing but the end action seems to be either direct or indirect inhibition. This is why they use Aspirin to decrease the incidence of colon cancer. Im not sure if this is an FDA approved use for Aspirin.

I remember way back in the 1990s an article in the American Journal of Epidemiology where, in a retrospective study it showed that women who took Motrin at least 4 days out of the week had a breast cancer rate 50% less than those who did not. Of course this was only one study.



Paul
donocco is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 11:14 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2017, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter